Thompson Davis & Co’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Thompson Davis & Co’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	$0	Hold	1	–	–	﹤0.01%	804
2018 Q2	$2K	Hold	1	–	–	﹤0.01%	630
2018 Q1	$2K	Buy	+1	New	+$2.23K	0.01%	581
2017 Q2	–	Sell	-4	Closed	-$2K	–	1201
2017 Q1	$2K	Hold	4	–	–	﹤0.01%	1074
2016 Q4	$3K	Hold	4	–	–	0.01%	986
2016 Q3	$4K	Hold	4	–	–	0.01%	895
2016 Q2	$3K	Hold	4	–	–	﹤0.01%	907
2016 Q1	$3K	Hold	4	–	–	﹤0.01%	909
2015 Q4	$4K	Sell	4 -2	-33%	-$2.64K	0.01%	905
2015 Q3	$6K	Hold	6	–	–	0.01%	811
2015 Q2	$12K	Buy	6 +2	+50%	+$2.84K	0.01%	680
2015 Q1	$4K	Hold	4	–	–	﹤0.01%	970
2014 Q4	$4K	Hold	4	–	–	﹤0.01%	1007
2014 Q3	$4K	Hold	4	–	–	0.01%	957
2014 Q2	$7K	Hold	4	–	–	0.01%	559
2014 Q1	$9K	Hold	4	–	–	0.01%	516
2013 Q4	$8K	Buy	+4	New	+$9.15K	0.01%	505

Other funds holding ONCT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Thompson Davis & Co's ONCT Position: Q3 2018 in Review

Thompson Davis & Co held its Oncternal Therapeutics, Inc. Common Stock (ONCT) position steady in Q3 2018 at 1 share worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #804.

Thompson Davis & Co first reported a position in ONCT in Q4 2013 and has held it in 17 quarters since. The position peaked at $12K in Q2 2015. 48 funds tracked by Wall St. Rank hold ONCT as of Q3 2018.

Thompson Davis & Co held 1 share of Oncternal Therapeutics, Inc. Common Stock worth $0 as of Q3 2018.
Thompson Davis & Co left its Oncternal Therapeutics, Inc. Common Stock share count unchanged in Q3 2018.
Oncternal Therapeutics, Inc. Common Stock made up ﹤0.01% of Thompson Davis & Co's portfolio in Q3 2018, its #804 holding.
Thompson Davis & Co first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q4 2013 and has held it in 17 quarters since.
Thompson Davis & Co's Oncternal Therapeutics, Inc. Common Stock position peaked at $12K in Q2 2015.
48 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.